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Background. There is limited knowledge of the effects of anaesthetics on left ventricular (LV)
diastolic function in humans. Our aim was to evaluate these effects in humans free from cardio-
vascular disease.
Methods. Sixty patients (aged 18–47 yr) who had no history or signs of cardiovascular disease
were randomized to receive general anaesthesia with halothane, sevoflurane or propofol. Echo-
cardiography was performed at baseline and during spontaneous respiration at 1 minimum
alveolar concentration (MAC) of the inhalational agents or propofol 4 mg ml1 (step 1), and
repeated during positive-pressure ventilation with 1 and 1.5 MAC of the inhalational agents or
with propofol 4 and 6 mg ml1 (steps 2A and 2B). Analysis of echocardiographic measurements
focused on heart rate corrected isovolumic relaxation time (IVRTc) and early diastolic peak
velocity of the lateral mitral annulus (Ea).
Results. IVRTc decreased from baseline to step 1 in the halothane group (82 [95% CI, 76–88] ms
and 74 [95% CI, 68–80] ms respectively; P=0.02), remained stable in the sevoflurane group
(78 [95% CI, 72–83] ms and 73 [95% CI, 67–81] ms; n.s.) and increased in the propofol
group (80 [95% CI, 74–86] ms and 92 [95% CI, 84–102] ms; P=0.02). Ea decreased in the propofol
group only (18.8 [95% CI, 16.5–19.9] cm s1 and 16.0 [95% CI, 14.9–17.9] cm s1; P=0.003). From
step 2A to step 2B, IVRTc increased further in the propofol group (109 [95% CI, 99–121] ms and
119 [95% CI, 99–135] ms; P=0.04) but remained stable in the other two groups. Ea did not change
from step 2A to step 2B.
Conclusions. Halothane and sevoflurane did not impair LV relaxation, whereas propofol caused
a mild impairment. However, the impairment by propofol was of a magnitude that is unlikely to
cause clinical diastolic dysfunction.
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Impaired diastolic function is a major cause of heart failure
in the general population. More than 40% of patients with
heart failure have normal systolic function of the heart but
compromised diastolic function.1 Concomitantly, impaired
diastolic function is expected to contribute to perioperative
heart failure. Nevertheless, knowledge about the signifi-
cance of diastolic function in the perioperative setting is
very limited, and the effects of anaesthetics on diastolic
function have been insufficiently evaluated in humans.
Until now, all available information has been obtained
from animal and laboratory data.2–4 Most studies indicate
an impairment of left ventricular (LV) relaxation by inhala-
tional agents but not by propofol.5–9
Diastolic LV function depends on a sequence of interre-
lated events. The phase of isovolumic myocardial relaxation
with a rapid LV pressure fall due to relaxation and elastic
recoil is followed by the filling phases. The rapid early filling
phase is related to the rate of myocardial relaxation and
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depends on the pressure gradient between the atrium and the
left ventricle. The late filling phase is related to active atrial
contraction.10
Doppler echocardiography is the method of choice for
non-invasive evaluation of diastolic function in
humans.3 10 11 Several Doppler indices closely correlate
with invasively derived indices of LV relaxation and provide
direct information on LV relaxation and filling.12
The aim of the present study was to evaluate the effects of
three different anaesthetics on LV diastolic function in
humans without known cardiovascular disease. The evalua-
tion was performed using echocardiography. Based on find-
ings in animals, we hypothesized that halothane and
sevoflurane, but not propofol, would impair LV relaxation
and early filling.5–9
Patients and methods
Patients
Following approval by the University Hospital of Basel
institutional review board and written informed consent,
61 patients undergoing minor surgical procedures under
general anaesthesia were enrolled. Exclusion criteria were
any history or signs of cardiac, pulmonary or systemic dis-
ease, any medication with cardiovascular effects or side
effects, age <18 yr or >50 yr and BMI >30 kg m2. A
computer-generated random list was used to assign patients
to halothane, sevoflurane or propofol anaesthesia.
After arrival in the preoperative area, intravenous access
was established and Ringer’s lactate administered to replace
the fluid deficit caused by overnight fasting. The deficit per
hour of fasting was calculated as follows: 4 ml kg1 for the
first 10 kg of body weight, 2 ml kg1 for the second 10 kg
and 1 ml kg1 for every additional kilogram. Twenty-five
per cent of the deficit was replaced before the start of the
study, a total of 30% by the end of step 1 and a total of 35%
by the end of step 2B. Two-lead electrocardiography and
pulse oximetry were monitored continuously, and arterial
pressure was measured non-invasively every 3 min (PCMS
Workstation 90308–15–03, SpaceLabs Inc., Redmond, WA,
USA). From induction of anaesthesia, end-tidal concentra-
tions of carbon dioxide, sevoflurane and halothane were
measured continuously at the tip of the laryngeal mask
or orotracheal tube (Caponomac Ultima, Datex, Helsinki,
Finland). Hypotension, defined as a decrease of >30% from
baseline in systolic arterial blood pressure, was treated with
phenylephrine (25–50 mg intravenous bolus).
The first (baseline) transthoracic echocardiography (TTE)
was performed with the patient awake and unpremedicated
in a partial left lateral position. The same position was used
during all further measurements. Thereafter, anaesthesia
was induced by inhalation of sevoflurane (Sevorane,
Abbott International Ltd, Abbott Park, IL, USA) or
halothane (Halocarbon Laboratories, River Edge, NJ, USA)
in 100% oxygen, or by intravenous infusion of propofol
(Diprivan, Zeneca Pharmaceuticals, Macclesfield,
Cheshire, UK) delivered by a target-controlled infusion
system (TCI, Diprifusor, Zeneca Pharmaceuticals). No
narcotics or opioids were used. After placement of a
laryngeal mask, the inspiratory oxygen concentration was
adjusted to 0.4, the inhalational agents to 1 minimum
alveolar concentration (MAC) (2% end-tidal concentration
of sevoflurane, 0.75% concentration of halothane) and pro-
pofol to 4 mg ml1. As soon as anaesthetic and haemo-
dynamic steady-state conditions were reached, a second
TTE was performed (step 1). In the propofol group, an
additional intravenous line was placed in a cubital vein of
the arm not used for the infusion of propofol and blood was
withdrawn at the end of steps 1, 2A and 2B for chroma-
tographic analysis of propofol blood concentrations
(modified from Plummer and colleagues13).
At the end of step 1, fentanyl 2 mg kg1 and rocuronium
0.6 mg kg1 were administered and the dose of sevoflurane,
halothane or propofol increased, as needed clinically for
tracheal intubation and intermittent positive pressure venti-
lation (IPPV) to normocapnia (end-tidal carbon dioxide
4.5–5 kPa) commenced. A transoesophageal echo probe
was placed in the oesophagus. When steady-state conditions
were reached at 1 MAC of the inhalational agents or intra-
venous propofol 4 mg ml1, transoesophageal echocardio-
graphy (TOE) was performed (step 2A). A second TOE was
performed after reaching steady-state conditions at 1.5 MAC
of the inhalational agents (3% end-tidal concentration of
sevoflurane, 1.1% end-tidal concentration of halothane) or
propofol 6 mg ml1 (step 2B), after which the patient under-
went the scheduled surgery.
Doppler echocardiography
All echocardiograms were obtained with a Sonos 5500
system (Philips Medical Systems, Best, The Netherlands)
according to current guidelines.10 12 14 A 1.8–2.1/3.6–4.1
MHz S4 probe was used for TTE, and a 4–7 MHz multiplane
probe was used for TOE. The echocardiographic data were
digitally stored for subsequent off-line analysis. Standard
LV short-axis and two- and four-chamber views were
obtained by the parasternal and apical views for TTE,
and by standard mid-oesophageal and transgastric views
for TOE. For the pulsed-wave Doppler recordings of mitral
inflow, the sample volume was positioned between the tips
of the open mitral leaflets using optimal alignment with
transmitral blood flow. For recordings of IVRT, the beam
was slightly moved towards the LV outflow tract to obtain
recordings of both LV inflow and LV outflow signals. For
recordings of pulsed-wave tissue Doppler imaging, the sam-
ple volume was placed at the lateral side of the mitral annu-
lus and the acoustic power and filter frequencies of the
system were set to the lowest possible values. The following
variables were measured: end-diastolic and end-systolic
areas (EDA and ESA, respectively), peak early and peak
late transmitral filling velocities (E and A, respectively),
IVRT, and early and late diastolic velocities of the lateral
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mitral annulus (Ea and Aa, respectively) and the systolic peak
velocity of the lateral mitral annulus (Vs). The following
parameters were calculated from these data: fractional
area change FAC=[(EDA–ESA)/EDA]·100), ratio E/A,
heart-rate-corrected IVRT (IVRTc=IVRT[RR interval]1/2)
and Ea/Aa. All variables were measured at end-expiration
over three, preferably consecutive, cardiac cycles and aver-
aged by an experienced physician-echocardiographer
blinded to the group allocation of the patient and to all
other study data. Blinding of the echocardiographer to the
step of the study was not possible as transthoracic and trans-
oesophageal recordings were used at different stages. To
determine intra- and interobserver variability, a random
sample of 25% of the cycles was submitted twice to a
first investigator and once to a second investigator. The
variabilities were calculated as the mean absolute difference
between the two readings divided by their mean and
expressed as a percentage.
Potential changes in LV diastolic function were assessed
by IVRT or IVRTc (if a significant change in heart rate had
occurred) and Ea. Increasing IVRTc or decreasing Ea
was interpreted as worsening of LV relaxation and diastolic
function.15 16
Statistical analysis
Continuous variables are presented as mean (95% CI). The
x2-test was used for analyses of dichotomous variables. After
testing the normal distribution by Kolmogorov–Smirnov
statistics, analyses of continuous variables were performed
by analysis of variance (ANOVA) for repeated measures
comparing baseline data with data of step 1, and data of
step 2A with those of step 2B. Thereafter, intergroup com-
parison was performed by one-way ANOVA followed by
Scheffe´’s post hoc test, and intragroup comparison was per-
formed by Bonferroni t-test. A P value <0.05 was considered
statistically significant. All statistical analyses were per-
formed using an SPSS for Windows 11.5 computer package
(SPSS Inc., Chicago, IL, USA). The sample-size calculation
was based on pilot data estimating that 20 patients per group
would allow for detection of a difference of 20% in Ea and
IVRTc with a power of 80% for intragroup comparison
(ANOVA for repeated measures), and that 14 patients
would allow for detection of the same differences with the
same power in intergroup comparison (ANOVA, three groups
of same size).
Results
There were no significant differences between the three
groups in any baseline parameters (Table 1). One patient
was excluded from the study because TTE at baseline
revealed a previously unknown but significant aortic regur-
gitation.
During anaesthesia with spontaneous respiration (step 1),
there was a similar decrease in mean arterial pressure in all
groups (Table 2) and no patient received phenylephrine.
Heart rate increased only in the propofol group. IVRTc
decreased in the halothane group, remained stable in the
sevoflurane group and increased in the propofol group.
IVRTc was prolonged in the propofol group compared
with the sevoflurane group. Ea remained stable in the
halothane and sevoflurane groups but decreased in the pro-
pofol group (Table 2 and Fig. 1A). FAC decreased in the
sevoflurane and halothane groups but remained unchanged
in the propofol group.
Phenylephrine was administered to three patients in
the halothane group and two in the sevoflurane group
(25–300 mg) during step 2A, and to four patients in the
halothane group and two in the sevoflurane group
(25–300 mg) during step 2B. In contrast, phenylephrine
was not required in the propofol group (P=n.s). Step 2B
was not performed in two patients in the halothane group
and one in the sevoflurane group because of hypotension
Table 1 Patient characteristics and baseline findings. Values are mean (95% CI)
or number (%). There were no differences between the groups
Halothane
(n=20)
Sevoflurane
(n=20)
Propofol
(n=20)
ASA I 15 (75) 18 (90) 15 (75)
Women 7 (35) 7 (35) 8 (40)
Age (yr) 30 (26–34) 29 (24–33) 30 (26–34)
Weight (kg) 69 (61–71) 68 (63–74) 65 (60–71)
Height (cm) 172 (167–178) 173 (169–176) 172 (167–176)
BMI (kg m2) 23 (22–25) 23 (22–24) 22 (21–23)
Haemoglobin (g l1) 146 (139–153) 142 (129–155) 146 (138–153)
Creatinine (mmol l1) 67 (60–74) 67 (58–77) 63 (56–69)
Table 2 Haemodynamic and main echocardiographic findings at baseline and during anaesthesia with 1 MAC halothane or sevoflurane, or propofol 4 mg ml1 under
spontaneous ventilation (step 1). Values are mean (95% CI). *P<0.05 vs baseline (intragroup comparison); {P<0.05 halothane vs propofol; zP<0.05 sevoflurane vs
propofol (intergroup comparison, anaesthetized). There were no differences in baseline findings. A more detailed set of data can be found at http://www.anaesthe-
sie.ch/publications/echodata.pdf
Halothane (n=20) Sevoflurane (n=20) Propofol (n=20)
Baseline Anaesthesia Baseline Anaesthesia Baseline Anaesthesia
IVRTc (ms) 82 (76–88) 74 (68–80)* 78 (72–83) 73 (67–81) 80 (74–86) 92 (84–102)*
z
Ea (cm s
1) 18.9 (16.7–21.1) 18.3 (16.6–20.0) 20.1 (18.2–22.2) 19.0 (17.4–21.7) 18.8 (16.5–19.9) 16.0 (14.9–17.9)*
FAC (%) 58 (54–61) 50 (47–54)* 55 (53–57) 50 (46–54)* 57 (54–59) 55 (52–58)
MAP (mm Hg) 83 (79–87) 72 (67–76)* 85 (80–89) 70 (67–73)* 80 (75–84) 67 (64–71)*
HR (beats min1) 64 (60–69) 62 (57–66) 63 (58–68) 62 (58–67) 63 (61–70) 76 (70–81)*{z
MAP, mean arterial pressure; HR, heart rate.
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(P=n.s). Mean arterial pressure was higher in the propofol
group than in the halothane group during step 2B.
IVRTc remained unchanged in the halothane and sevo-
flurane groups but increased in the propofol group. IVRTc
was prolonged in the propofol group compared with the
sevoflurane and halothane groups during steps 2A and 2B.
Ea did not change from step 2A to step 2B in any study group
(Table 3 and Fig. 1B). FAC decreased in all study groups.
Intraobserver variability was 5(SD 5)% (TTE) and 9(10)%
(TOE) for IVRT, and 3(3)% and 4(5)% for Ea. The corre-
sponding values for interobserver variability were 14(10)%
and 10(8)% for IVRT, and 4(3)% and 3(4)% for Ea.
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Fig 1 (A) Changes (95% CI) from baseline to anaesthesia during spontaneous respiration (step 1). (B) Changes (95% CI) from anaesthesia with 1 MAC
halothane or sevoflurane and propofol 4 mg ml1 (step 2A) to anaesthesia with 1.5 MAC and halothane or sevoflurane and propofol 6 mg ml1 during IPPV
(step 2B). *P<0.05 intergroup comparison; **P<0.05 intragroup comparison (ANOVA for repeated measures); n.s., not significant.
Table 3 Haemodynamic and main echocardiographic findings during anaesthesia with 1 and 1.5 MAC halothane or sevoflurane, or propofol 4 or 6 mg ml1 under
IPPV (steps 2A and 2B). Values are mean (95% CI). ¶Two patients in the halothane group and one patient in the sevoflurane group were excluded from step 2B because
of hypotension; *P<0.05 step 2A vs step 2B (intragroup comparison); {P<0.05 halothane vs propofol; zP<0.05 sevoflurane vs propofol (intergroup comparison of steps
2A and 2B, respectively). A more detailed set of data can be found at http://www.anaesthesie.ch/publications/echodata.pdf
Halothane Sevoflurane Propofol Intergroup comparison
1 MAC
(step 2A, n=20)
1.5 MAC
(step 2B, n=18¶)
1 MAC
(step 2A, n=20)
1.5 MAC
(step 2B, n=19¶)
4 mg ml1TCI
(step 2A, n=20)
6 mg ml1TCI
(step 2B, n=20)
Step 2A Step 2B
IVRTc (ms) 94 (89–107) 94 (83–104) 92 (86–100) 95 (89–101) 109 (99–121) 119 (99–135)* {z {z
Ea (cm s
1) 14.4 (13.2–16.6) 15.0 (13.9–16.7) 15.4 (13.9–16.6) 15.8 (14.3–17.2) 13.5 (10.6–15.1) 13.7 (11.3–15.1)
FAC (%) 41 (36–46) 35 (30–41)* 44 (39–49) 37 (31–41)* 52 (45–58) 46 (41–50)* { {z
MAP (mm Hg) 68 (61–72) 65 (58–68)* 71 (68–74) 68 (65–73)* 73 (69–79) 74 (64–71) { {
HR (beats min1) 61 (55–66) 63 (55–67) 66 (61–69) 68 (63–71) 70 (63–75) 67 (61–72)*
MAP, mean arterial pressure; HR, heart rate.
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Discussion
Our echocardiography study found that halothane and
sevoflurane did not impair LV relaxation and early filling
in the subjects who had no history or signs of cardiovascular
disease. However, echocardiographic parameters indica-
ted a worsening of diastolic function during propofol
administration.
During spontaneous ventilation (step 1), halothane and
sevoflurane at 1 MAC had similar effects on LV diastolic
function. We found no evidence of impairment of LV relaxa-
tion and early filling, as IVRTc and Ea did not change. In
contrast, halothane and sevoflurane impaired LV late filling.
LV late filling is determined mainly by left atrial systolic
function, a parameter that was not measured in this study.
However, it has been previously shown in animal and human
studies that left atrial systolic function is impaired by
inhalational agents.17 18
In contrast with halothane and sevoflurane, IVRTc
increased and Ea decreased significantly during the admin-
istration of propofol 4 mg ml1, indicating some impairment
of LV relaxation and early filling. IVRTc and Ea are estab-
lished echocardiography indicators for clinical assessment
of diastolic function: IVRT is an indicator of LV relaxation,
and it changes in parallel with the time constant t of the
fall of LV pressure, which is the standard indicator of LV
relaxation in invasive studies,15 and Ea is a tissue Doppler
derived parameter of LV performance, which has been
described as a preload- and heart-rate-independent indicator
of LV relaxation and global LV diastolic function.16 19 How-
ever, the only intergroup difference that reached statistical
significance was the IVRTc between propofol and sevoflur-
ane. Moreover, it should be noted that the increase in heart
rate observed in the propofol group may have influenced our
findings. Although LV early filling is determined mainly by
LV relaxation, it is modulated by the heart rate20 and the
pressure gradient between the left atrium and left ventricle.21
Therefore the increased heart rate may have made some
contribution to the observed impairment of LV early filling
in the propofol group. An additional finding was that pro-
pofol had only minimal effects on LV late filling, which also
contrasts with the inhalational agents.
During IPPV (step 2), the effects at the lower anaesthetic
doses were similar to those in step 1, but increased at the
higher doses. In particular, we found no evidence for impair-
ment of LV relaxation and LV early filling by halothane or
sevoflurane. In contrast, the change in IVRTc in the propofol
group indicated a dose-dependent impairment of LV relaxa-
tion. During spontaneous respiration, we found a reduction
in late LV filling with the inhalational agents but not with
propofol. This difference persisted during IPPV. In contrast,
the difference in LV early filling disappeared during IPPV
and Ea was similar in all study groups. We suspect that
the negative effect on venous return22 of anaesthesia with
muscle paralysis and IPPV may have attenuated the effects
of the three agents on early filling.
The absence of impairment of diastolic function by inha-
lational agents contrasted with the clear impairment of sys-
tolic function (i.e. FAC) by halothane and, to a lesser extent,
sevoflurane. The stability of IVRTc during impaired LV
systolic function strengthens the evidence for the lack of
impairment of LV relaxation and early filling by the inhala-
tional agents as diastolic function is dependent on systolic
function. In particular, a decrease in systolic function is
associated with prolonged t in experimental studies.23
The lack of impairment of LV relaxation and early filling
caused by either halothane or sevoflurane contrasts with
results in animal and in vitro studies which have shown
impairment of LV relaxation, a negative lusitropic effect,
by inhalational agents.5–7 Inhalational agents alter calcium
homeostasis at several subcellular targets within the myo-
cyte in vitro.3 24 During systole, they decrease available
intracellular calcium causing negative inotropic effects,
and during diastole they interfere with calcium reuptake
from the cytosol into the sarcoplasmatic reticulum.24
Because myocardial relaxation, i.e. early diastolic function,
depends on this active energy-consuming calcium reup-
take,25 inhalational agents might affect diastolic function.
Results from animal studies have indeed demonstrated
changes in myocardial relaxation and diastolic filling
induced by these agents.5–7 Our results may differ from
these previous studies as we studied humans in vivo rather
than animals or myocardial tissue in vitro, and we used non-
invasive Doppler echocardiography and IVRT measurement
rather than t. However, IVRT changes in parallel with t,15
and IVRT should at least indicate directional changes of t. In
addition, we used clinical doses of anaesthetic agents in our
study rather than the much higher doses often used in vitro
studies. These differences in study design make a
direct comparison with previous findings difficult. How-
ever, our results are based on different echocardiographic
parameters consistently indicating that 1–1.5 MAC of
halothane or sevoflurane in healthy subjects does not impair
LV relaxation.
Our second main finding, of impaired LV relaxation by
propofol, also contrasts with animal studies which have
found no effect of propofol on global LV diastolic func-
tion.8 9 This finding also contrasts with a recent echocardio-
graphic study in humans in which very low doses of propofol
were used for conscious sedation.26 Nevertheless, our results
might be explained by the in vitro findings that propofol acts
on sarcolemmal calcium channels, impairing reuptake of
calcium by the sarcoplasmatic reticulum,27 and modulates
phosphorylation of the contractile muscle.28 These mechan-
isms are directly involved in myocardial muscle relaxation.
However, the impairment of diastolic function by propofol
was mild and did not cause clinical diastolic dysfunction in
any of the subjects.
The results of the present study are based on non-invasive
evaluation of haemodynamics and myocardial performance.
Thus direct information on filling pressures and the decrease
in LV isovolumetric pressure or its time constant t are not
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available. This limitation prevented a definitive conclusion
as to what extent the observed changes in indices of LV
relaxation in the propofol group were caused by worsening
of LV diastolic function or by haemodynamic changes.
However, our investigation was based on Doppler echocar-
diography, which is the method of choice for routine non-
invasive evaluation of diastolic function in humans.10 11 In
addition, our conclusions were based on two different echo-
cardiographic parameters of diastolic function using differ-
ent echocardiographic techniques and parallel changes in
these parameters were observed.
A further limitation is the questionable equipotency of the
inhalational agents and propofol. However, our primary
conclusions were based on intragroup comparisons of the
different steps of anaesthesia, and these comparisons are
unaffected by the relative potency of the agents. In addition,
studies adapting the MAC concept to propofol target con-
centrations and blood concentrations found comparable
values to those used in our study.29 30
In conclusion, we have found that halothane and sevo-
flurane did not influence LV relaxation but propofol caused
some impairment. However, the magnitude of impairment
by propofol was small and unlikely to cause clinically
significant diastolic dysfunction in patients who have no
cardiovascular disease.
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